A107 POSTOPERATIVE OUTCOMES AMONG USTEKINUMAB TREATED CROHN’S DISEASE PATIENTS: A MULTICENTRE CANADIAN PROVINCIAL EXPERIENCE

BACKGROUND: Ustekinumab (UST), an anti IL12/23 inhibitor, has been recently approved for the treatment of moderate to severe Crohn’s disease (CD) in Europe and the United States. In Canada, UST has been used off-label for CD patients failing anti-TNF therapy. AIMS: We aim to review postoperative saf...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Can Assoc Gastroenterol
Hlavní autoři: Shim, H, Ma, C, Al-Farhan, H, Aldarmaki, A K, Pang, J, Seow, C, Fedorak, R, Devlin, S, Dieleman, L A, Kaplan, G G, Novak, K L, Kroeker, K I, Halloran, B P, Panaccione, R
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2018
Témata:
Poster Presentations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6507798/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy008.108
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky